人骨转移瘤肿瘤浸润淋巴细胞的过继免疫治疗

Adoptive Immunotherapy of Skeletal Metastatic Neoplasma Using Tumor Infiltrating Lymphocytes

肿瘤浸润淋巴细胞(TIL)的杀伤肿瘤细胞效应比淋巴因子活化杀伤细胞(LAK)更为有效低毒。作者用手术与活检的方法从骨转移瘤标本中分离TIL,经体外重组白细胞介素—2(rIL—2)激活并扩增,过继转输10例骨转移瘤病例,完全应答1例,部分应答2例,弱应答3例,无应答4例。有效应答30%。

In order to look for more efficient and less toxic activated killer(LAK)cell than lymphokine in Adoptive Immunotherapy(AIT), Tumor Infiltrating Lymphocytes(TILs)were isolated from surgery and biopy samples obtained from 10 patients with skeletal metastatic neoplasma during the period of 1990 3 to 1992 10. TILs activated and expanded in vitro were adoptively transferred to patients with skeletal metastatic neoplasma. One having complete response, two partial response, three minor response, four nonresponse to TILs immunotherapy were observed. Valid response was 30%. This pilot study using the adoptive transfer of large numbers of TILs to treat patients with advance malignant neoplasma had obtained encourging results.